// App-Quantinova.ai

: The First Report of Third-Generation TKI Olverembatinib in Adult Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia with T315I Mutation and Relapsed Disease

Researchers

Presenter

  • Weiyang Liu

Principal Investigators

  • Yuanfang Liu

  • Yongmei Zhu

  • Xiangqin Weng

  • Cheng Wang

  • Wanyan Ouyang

  • Jie Xu

  • Jin Wang

  • Jian-qing Mi

Medical Centers

  • Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Vincristine

  • Prednisone

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved